CD163 and breast carcinoma: As the breast cancer subtype also has been proposed to associate with CD163 [7–9, 11, 12], we next investigated the prognostic impact of CD163+ immune cells in the PT, stratified according to IHC-subtype as this was used to determine MBC treatment (Fig. 4).